SUNPHARMA

Market Context: As global markets face pressure, Sun Pharma is being watched as a defensive hedge. However, technical indicators are currently flashing mixed signals that traders need to navigate carefully. Key Drivers: US Revenue: With 35% of revenue coming from the US, any shifts in tariff policies are the primary "risk-reward" driver for this stock in 2026. Trading at a P/E of 37x, slightly above the sector average of 36.5x. Technical Setup: The Bearish Case: RSI is currently near 41 (Sell zone), and it's trading below its 5-day and 50-day moving averages. The Bullish Case: MACD remains positive at 0.45, and the 200-day EMA at ₹1,698 is acting as a massive "Buy on Dip" magnet. Strategy Insight: Watch the ₹1,713 level. If the stock fails to cross this, it might consolidate further. A move above it could trigger a short-covering rally.